T1	condition 14 33	cardiac dysfunction
T4	total-participants 750 753	130
T5	eligibility 754 818	adult women with early breast cancer and no serious co-morbidity
T6	control 926 934	placebos
T7	outcome-Measure 1013 1027	change in LVEF
T8	outcome 1156 1216	no interaction between candesartan and metoprolol treatments
T12	intervention 163 189	candesartan and metoprolol
T2	outcome 1253 1257	LVEF
T3	cv-cont-mean 1262 1265	2.6
T9	iv-cont-mean 1327 1330	0.8
T10	outcome 1507 1511	LVEF
